日前,国家药监局宣布多款创新医疗器械获批上市,其中,一次性使用外周血管血栓旋切导管为国内首创,并达到国际先进水平。与此同时,又有十多款产品公告进入创新医疗器械特别审批程序。公开数据显示,2025年国家药监局已公告122款产品进入创新医疗器械特别审批程序,较2024年近乎翻倍。中国创新医疗器械,即将迎来自己的“创新药”时刻?01国内创新医疗器械BD也疯狂回顾中国创新药的崛起,从2024年开始,中国...
Source Link日前,国家药监局宣布多款创新医疗器械获批上市,其中,一次性使用外周血管血栓旋切导管为国内首创,并达到国际先进水平。与此同时,又有十多款产品公告进入创新医疗器械特别审批程序。公开数据显示,2025年国家药监局已公告122款产品进入创新医疗器械特别审批程序,较2024年近乎翻倍。中国创新医疗器械,即将迎来自己的“创新药”时刻?01国内创新医疗器械BD也疯狂回顾中国创新药的崛起,从2024年开始,中国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.